HAYWARD, Calif. and NEW YORK–(BUSINESS WIRE)–Eikon Therapeutics Inc., a biotechnology company that applies advanced engineering and high-performance computing to identify important new drugs, today announced it has entered into a lease with Alexandria Real Estate Equities, Inc. for its new East Coast base of operations located at the Alexandria Center® for Life Science in New York City.
The 25,000 square foot mixed-use facility will allow Eikon to establish a clinical development arm, expand existing research functions, attract top talent to both U.S. coasts, and explore potential collaborations with East Coast entities.
Eikon’s Chief Medical Officer, Roy Baynes, MB, BCh, MMed, PhD, will lead operations at the company’s East Coast site. “With this state-of-the-art facility, we have access to the New York metro area’s unrivaled talent pool, including physicians and scientists trained at some of the world’s most renowned universities, clinical research institutes and biopharmaceutical companies, Baynes said.
“Eikon is proud to join the community of life sciences companies based in the New York area, and we are privileged to have Dr. Roy Baynes lead this expansion,” said Roger M. Perlmutter, MD, PhD. , Chairman and CEO of Eikon Therapeutics. “Roy’s deep expertise in clinical development allows us to attract talented physician-scientists to Eikon’s research enterprise.
“We are honored to extend our strategic relationship with Eikon,” said John Cunningham, Executive Vice President – Regional Market Manager – NYC at Alexandria Real Estate Equities, Inc. “The Alexandria Center will provide Eikon with an inspiring environment from which to recruit and retain top talent as the company advances its revolutionary platform.”
Eikon recently announced that it is also working with Alexandria to develop the company’s new 285,000 square foot global headquarters in Millbrae, California.
Eikon Therapeutics was represented in this transaction by Cushman & Wakefield.
About Eikon Therapeutics
Eikon Therapeutics is a drug discovery and development company. Our proprietary platform leverages super-resolution microscopy, cutting-edge engineering and Nobel Prize-winning high-performance computing to bring important new medicines to patients with serious diseases. Eikon scientists measure the real-time movement of individual proteins in living cells to develop differentiated therapies. Eikon is headquartered in California and can be found online through our website or at Twitter or LinkedIn.